Vertex's cystic fibrosis drugs work, but they're too expensive, ICER finds

Earlier this month, Reshma Kewalramani took over the reins as Vertex Pharmaceuticals’ CEO — she will now be tasked with grappling with criticism from cost-effectiveness watchdog ICER, which on Monday issued a report suggesting that despite the health gains offered by its suite of cystic fibrosis drugs, their prices are far too high to be sustainable for patients and health care systems.